Stimuli-responsive nanodrug self-assembled from amphiphilic drug-inhibitor conjugate for overcoming multidrug resistance in cancer treatment
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 9 (20) , 5755-5768
Abstract
Severe multidrug resistance (MDR) often develops in the process of chemotherapy for most small molecule anticancer drugs, which results in clinical chemotherapy failures.Keywords
This publication has 47 references indexed in Scilit:
- Redox compartmentalization in eukaryotic cellsBiochimica et Biophysica Acta (BBA) - General Subjects, 2008
- The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated effluxEuropean Journal of Pharmaceutical Sciences, 2006
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrineCancer Chemotherapy and Pharmacology, 2004
- The role of glutathione in cancerCell Biochemistry and Function, 2004
- Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activitiesAdvanced Drug Delivery Reviews, 2003
- Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels.2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2Pharmacogenomics, 2001
- Oxidized Redox State of Glutathione in the Endoplasmic ReticulumScience, 1992